AOTMiT: Transparency Council on AD and ulcerative colitis drugs, among others

The agenda includes:

Preparation of positions on drug evaluation:

• Adtralza (tralokinumabum) under drug program B.124 "Treatment of patients with severe forms of atopic dermatitis (ICD-10: L20)."
• Rinvoq (upadacitinibum) under drug program B.55 "Treatment of patients with ulcerative colitis (UC) (ICD-10: K51)."

Preparation of opinions on draft health policy programs of local government units:

• "Subsidy for infertility treatment by in vitro fertilization for residents of the city of Zduńska Wola for 2023",
• "Infertility treatment by in vitro fertilization for residents of the city of Bialystok in 2023 implemented from Citizens' Budget 2023".

Preparation of an opinion on the appropriateness of amending the eligibility and dosage criteria for the medicinal product Ozurdex (dexamethasonum), implant into the vitreous body in a 700 mcg applicator, in part B of the drug program B.70 "Treatment of patients with retinal diseases (ICD-10: H35.3, H36.0)", i.e. "Treatment of patients with diabetic macular edema (DME)".

Source: AOTMiT